Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein

被引:25
|
作者
Bauer, Michelle J. [1 ]
Georgousakis, Melina M. [1 ]
Vu, Therese [1 ]
Henningham, Anna [2 ]
Hofmann, Andreas [3 ]
Rettel, Mandy [4 ,5 ]
Hafner, Louise M. [6 ]
Sriprakash, Kadaba S. [1 ]
McMillan, David J. [1 ]
机构
[1] Queensland Inst Med Res, Bacterial Pathogenesis Lab, Brisbane, Qld 4029, Australia
[2] Univ Queensland, Sch Chem & Mol Biosci, Australian Infect Dis Res Ctr, St Lucia, Qld 4072, Australia
[3] Griffith Univ, Eskitis Inst Cell & Mol Therapies, Struct Chem Program, Nathan, Qld 4111, Australia
[4] Univ Appl Sci, Hsch Lausitz FH, D-01968 Senftenberg, Germany
[5] Univ Melbourne, Fac Vet Sci, Melbourne, Vic 3010, Australia
[6] Queensland Univ Technol, IHBI, Program Infect Dis, Brisbane, Qld 4001, Australia
基金
英国医学研究理事会;
关键词
Streptococcus pyogenes; M-protein; Vaccine; GROUP-A STREPTOCOCCUS; B-CELL EPITOPES; T-CELL; INTRANASAL IMMUNIZATION; ANTIBODIES; EMM; IMMUNOGENICITY; SEROTYPES; IDENTIFICATION; PATHOGENESIS;
D O I
10.1016/j.vaccine.2011.12.115
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A major challenge for Streptococcus pyogenes vaccine development is the identification of epitopes that confer protection from infection by multiple S. pyogenes M-types. Here we have identified and characterised the distribution of common variant sequences from individual repeat units of the C-repeat region (CRR) of M-proteins representing 77 different M-types. Three polyvalent fusion vaccine candidates (SV1, SV2 and SV3) incorporating the most common variants were subsequently expressed and purified, and demonstrated to be alpha-helical by Circular Dichroism (CD), a secondary conformational characteristic of the CRR in the M-protein. Antibodies raised against each of these constructs recognise M-proteins that vary in their CRR, and bind to the surface of multiples. pyogenes isolates. Antibodies raised against SV1, containing five variant sequences, also kill heterologous S. pyogenes isolates in in vitro bactericidal assays. Further structural characterisation of this construct demonstrated the conformation of SV1 was stable at different pHs, and thermal unfolding of SV1 is a reversible process. Our findings demonstrate that linkage of multiple variant sequences into a single recombinant construct overcomes the need to embed the variant sequences in foreign helix promoting flanking sequences for conformational stability, and demonstrates the viability of the polyvalent candidates as global S. pyogenes vaccine candidates. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2197 / 2205
页数:9
相关论文
共 12 条
  • [1] ROLE OF THE CONSERVED C-REPEAT REGION OF THE M-PROTEIN OF STREPTOCOCCUS-PYOGENES
    PEREZCASAL, J
    OKADA, N
    CAPARON, MG
    SCOTT, JR
    MOLECULAR MICROBIOLOGY, 1995, 15 (05) : 907 - 916
  • [2] ASSEMBLY AND ANALYSIS OF A FUNCTIONAL VACCINIA VIRUS AMPLICON CONTAINING THE C-REPEAT REGION FROM THE M-PROTEIN OF STREPTOCOCCUS-PYOGENES
    HRUBY, DE
    SCHNEEWIND, O
    WILSON, EM
    FISCHETTI, VA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (08) : 3190 - 3194
  • [3] AN M-PROTEIN WITH A SINGLE C-REPEAT PREVENTS PHAGOCYTOSIS OF STREPTOCOCCUS-PYOGENES - USE OF A TEMPERATURE-SENSITIVE SHUTTLE VECTOR TO DELIVER HOMOLOGOUS SEQUENCES TO THE CHROMOSOME OF S-PYOGENES
    PEREZCASAL, J
    PRICE, JA
    MAGUIN, E
    SCOTT, JR
    MOLECULAR MICROBIOLOGY, 1993, 8 (05) : 809 - 819
  • [4] Predicted Coverage and Immuno-Safety of a Recombinant C-Repeat Region Based Streptococcus pyogenes Vaccine Candidate
    McNeilly, Celia
    Cosh, Samantha
    Vu, Therese
    Nichols, Jemma
    Henningham, Anna
    Hofmann, Andreas
    Fane, Anne
    Smeesters, Pierre R.
    Rush, Catherine M.
    Hafner, Louise M.
    Ketheesan, Natkuman
    Sriprakash, Kadaba S.
    McMillan, David J.
    PLOS ONE, 2016, 11 (06):
  • [5] LIMITED REPERTOIRE OF THE C-TERMINAL REGION OF THE M-PROTEIN IN STREPTOCOCCUS-PYOGENES
    RELF, WA
    SRIPRAKASH, KS
    FEMS MICROBIOLOGY LETTERS, 1990, 71 (03) : 345 - 350
  • [6] M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats
    Vohra, H
    Dey, N
    Gupta, S
    Sharma, AK
    Kumar, R
    McMillan, D
    Good, MF
    RESEARCH IN MICROBIOLOGY, 2005, 156 (04) : 575 - 582
  • [7] Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development
    Williamson, Deborah A.
    Smeesters, Pierre R.
    Steer, Andrew C.
    Morgan, Julie
    Davies, Mark
    Carter, Philip
    Upton, Arlo
    Tong, Stephen Y. C.
    Fraser, John
    Moreland, Nicole J.
    BMC INFECTIOUS DISEASES, 2016, 16
  • [8] Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development
    Deborah A Williamson
    Pierre R Smeesters
    Andrew C Steer
    Julie Morgan
    Mark Davies
    Philip Carter
    Arlo Upton
    Stephen Y.C. Tong
    John Fraser
    Nicole J Moreland
    BMC Infectious Diseases, 16
  • [9] M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP)
    Jamie-Lee S. Mills
    Cesar M. Jayashi Flores
    Simone Reynolds
    Christine Wun
    Ainslie Calcutt
    S. Ben Baker
    Senthil Murugappan
    Alexandra C. I. Depelsenaire
    Jessica Dooley
    Paul V. Fahey
    Angus H. Forster
    Manisha Pandey
    Michael F. Good
    npj Vaccines, 5
  • [10] Author Correction: M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP)
    Jamie-Lee S. Mills
    Cesar M. Jayashi Flores
    Simone Reynolds
    Christine Wun
    Ainslie Calcutt
    S. Ben Baker
    Senthil Murugappan
    Alexandra C. I. Depelsenaire
    Jessica Dooley
    Paul V. Fahey
    Angus H. Forster
    Manisha Pandey
    Michael F. Good
    npj Vaccines, 5